CTIS2023-507233-19-00招募中1 期
A Phase 2/3, Multicenter, Open-label Trial to Evaluate the Long-term Safety, Tolerability, and Efficacy of Sibeprenlimab Administered Subcutaneously in Subjects with Immunoglobulin A Nephropathy - 417-201-00012
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 525
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Subjects who completed Trial 417-201-00007 (at least 20 of the 26 doses and the end-of-trial visit) or Trial VIS649-201 (at least 9 of the 12 doses and the end-of-trial visit) without safety concerns and who, in the opinion of the investigator, could potentially benefit from treatment with sibeprenlimab for IgAN., Subject has eGFR = 20 mL/min/1.73 m2, calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula., Ability to provide written, informed consent prior to initiation of any trial-specific procedures, and ability, in the opinion of the principal investigator, to comply with all the requirements of the trial.
排除标准
- •Subjects who have not completed participation in Trials 417-201-00007 or VIS649-201, Subject has a body mass index < 16 kg/m2., Subject has received an organ transplant (ie, solid or a bone marrow or hematologic stem cell transplantation)., Subject is currently receiving, or has received within 16 weeks prior to enrollment, systemic immunosuppression (note: topical, ophthalmic, rectal, intra-articular, inhaled corticosteroids, and short courses of oral/intravenous steroids [= 14 days] are allowed)., Subject has participated in another interventional clinical trial (other than Trials 417-201-00007 and VIS649-201) and received another investigational drug within 30 days prior to the administration of IMP or 5 half-lives from last investigational drug administration, whichever is longer., Subject has any chronic infectious disease (eg, chronic urinary tract infection; chronic sinusitis; bronchiectasis; active pulmonary or systemic tuberculosis; chronic viral hepatitis, such as hepatitis C or hepatitis B [defined as positive for hepatitis B surface antigen]; or human immunodeficiency virus [HIV] infection)., Subject has acute infectious disease at the time of screening. Note: Enrollment can be considered if the acute infection has resolved within the screening window, defined as resolution of acute clinical signs, symptoms, and related clinical laboratory parameters. Consultation between the trial site investigator and the medical monitor and/or sponsor should occur in case of any questions., Subject has Type 1 diabetes., Subject has uncontrolled Type 2 diabetes, as evidenced by a screening hemoglobin A1c (HbA1c) value > 8%. Subjects will be excluded if their anti-diabetic regimen is not stable. A stable anti-diabetic regimen is defined as either diet and exercise therapy alone or in combination with any approved anti-diabetic medication in which the doses of oral or noninsulin injectable medications have not changed during the 8 weeks prior to enrollment; or the doses of long-acting insulin or intermediate-acting insulin have not varied by more than 20% during the 8 weeks prior to enrollment., Subject has uncontrolled hypertension (defined as systolic blood pressure > 140 mmHg or diastolic blood pressure > 90 mmHg)., Subject who has a recent history (ie, within the past year) of alcohol or drug/chemical abuse that would, based on the investigator’s clinical judgement, interfere with the subject’s ability to participate in the trial., Subjects with treatment-limiting adverse events (AEs) during Trials 417-201-00007 or VIS649-201 considered related to IMP per investigator judgement that would preclude rollover into this trial., Subject is judged by the investigator or the medical monitor to be inappropriate for the trial., Subjects receiving any of the prohibited medications within the specified periods or who would be likely to require prohibited concomitant therapy during the trial., Noncompliance, due to subject’s repeated failure to follow trial procedures during the course of their participation in Trials 417-201-00007 and VIS649-201 (eg, subjects deemed to be noncompliant with the visit schedule, trial assessments, or treatment regimen). The medical monitor should be contacted if the investigator is unsure of a subject’s eligibility., Subjects who have a positive pregnancy test result prior to receiving IMP., Heterosexually biological active males or subjects of childbearing potential, or their partners, who do not agree to adhere to c
研究者
相似试验
招募中
2 期
Trial of Sibeprenlimab in the Treatment of Immunoglobulin A NephropathyJPRN-jRCT2031220273Yano Hisako600
招募中
2 期
Trial of Sibeprenlimab in the Treatment of Immunoglobulin A NephropathyCTRI/2024/02/062883
进行中（未招募）
1 期
This is a study to evaluate the long term safety of Tolvaptan in adults with chronic kidney disease.Autosomal Dominant Polycystic Kidney Disease (ADPKD)MedDRA version: 20.0 Level: LLT Classification code 10036046 Term: Polycystic kidney, autosomal dominant System Organ Class: 100000004850EUCTR2014-001516-19-BEOtsuka Pharmaceutical Development & Commercialization,2,500
进行中（未招募）
1 期
This is a study to evaluate the long term safety of Tolvaptan inadults with chronic kidney disease.Autosomal Dominant Polycystic Kidney Disease (ADPKD)MedDRA version: 18.0Level: LLTClassification code 10036046Term: Polycystic kidney, autosomal dominantSystem Organ Class: 100000004850EUCTR2014-001516-19-ESOtsuka Pharmaceutical Development & Commercialization,2,500
进行中（未招募）
不适用
This is a study to evaluate the long term safety of Tolvaptan inadults with chronic kidney disease.Autosomal Dominant Polycystic Kidney Disease (ADPKD)MedDRA version: 17.1Level: LLTClassification code 10036046Term: Polycystic kidney, autosomal dominantSystem Organ Class: 100000004850EUCTR2014-001516-19-FROtsuka Pharmaceutical Development & Commercialization,2,500